Condition (MeSH)
Respiratory System Abnormalities
ClinicalTrials.gov lists 53 trials for Respiratory System Abnormalities or a narrower condition beneath it. ReCode Therapeutics has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
8 of the 53 trials are tagged with Respiratory System Abnormalities itself; the rest are tagged with a narrower condition beneath it.
When did Respiratory System Abnormalities trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 5 |
| 2022 | 6 |
| 2021 | 3 |
| 2020 | 5 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Respiratory System Abnormalities trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
| Not applicable | 17 |
| Observational | 25 |
How many Respiratory System Abnormalities trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 8 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 27 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Respiratory System Abnormalities trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| ReCode Therapeutics | 4 |
| Umraniye Education and Research Hospital | 2 |
Which drugs are being tested for Respiratory System Abnormalities? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Betamethasone | 1 |
| Desflurane | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| RCT1100 | 3 |
| Mitomycin C 0.02% | 2 |
| Olfactory mucosa-derived mesenchymal stem cells | 2 |
| Ropivacaine 2 % | 1 |
| 1% Sevoflurane | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Respiratory System Abnormalities trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiopulmonary insufficiency requiring ECMO | 4 | 1 |
| Cardiac arrest requiring CPR and medications | 3 | 1 |
| Seizures | 3 | 1 |
| Need for dialysis | 2 | 1 |
| Psychiatric emergency | 1 | 1 |
Which publications cover Respiratory System Abnormalities? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities. | American journal of respiratory and critical care medicine | 2022 | Yes |
| Effect of lung hypoplasia on the cardiorespiratory transition in newborn lambs. | Journal of applied physiology (Bethesda, Md. : 1985) | 2019 | Yes |
| Midface and upper airway dysgenesis in FGFR2-related craniosynostosis involves multiple tissue-specific and cell cycle effects. | Development (Cambridge, England) | 2018 | Yes |
| Images in Anesthesiology: Congenital Pulmonary Airway Malformation. | Anesthesiology | 2017 | Yes |
| Prenatal and Postnatal Management of Congenital Pulmonary Airway Malformation. | Neonatology | 2016 | Yes |
Showing 5 of 12 publications.
Sub-conditions in MeSH (8)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.